Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer.

Publication Type:

Journal Article


BMC cancer, Volume 10, p.244 (2010)


2010, Animals, Antineoplastic Agents, Hormonal, Cell Line, Tumor, Cell Proliferation, Center-Authored Paper, Clinical Research Division, DIHYDROTESTOSTERONE, estradiol, Estrogen Antagonists, Genomics Core Facility, Human Biology Division, Humans, Male, mass spectrometry, MICE, Mice, SCID, Orchiectomy, Prostatic Neoplasms, Receptors, Estrogen, Shared Resources, TESTOSTERONE, Time Factors, Tumor Burden, Xenograft Model Antitumor Assays


Estrogens suppress tumor growth in prostate cancer which progresses despite anorchid serum androgen levels, termed castration resistant prostate cancers (CRPC), although the mechanisms are unclear. We hypothesize that estrogen inhibits CRPC in anorchid animals by suppressing tumoral androgens, an effect independent of the estrogen receptor.